NRX Pharmaceuticals
NRXP
20 hedge funds and large institutions have $44.1M invested in NRX Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
6% more capital invested
Capital invested by funds: $41.4M → $44.1M (+$2.66M)
5% more funds holding
Funds holding: 19 → 20 (+1)
0.25% more ownership
Funds ownership: 4.73% → 4.98% (+0.25%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LIM
Longfellow Investment Management
Boston,
Massachusetts
|
+$966K |
| 2 |
RCM
Rivernorth Capital Management
West Palm Beach,
Florida
|
+$596K |
| 3 |
BI
Bulldog Investors
Saddle Brook,
New Jersey
|
+$394K |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$348K |
| 5 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
+$240K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCL
Glazer Capital LLC
New York
|
-$201K |
| 2 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
-$121K |
| 3 |
KIM
Karpus Investment Management
Pittsford,
New York
|
-$18.9K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$13K |
NRXP Hedge Fund Activity: Q3 2018 in Review
20 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in NRX Pharmaceuticals (NRXP) for Q3 2018, worth a combined $44.1M — up 6.4% from $41.4M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new NRXP positions and 1 closed out — a net gain of 1 holder — while 5 added to existing stakes and 3 trimmed.
The largest buyer was Longfellow Investment Management, opening a new position worth an estimated $966K. The largest seller was Glazer Capital LLC, cutting an estimated $201K.
- 20 institutional investors held NRX Pharmaceuticals (NRXP) as of Q3 2018, up from 19 in Q2 2018.
- Funds reported $44.1M of NRX Pharmaceuticals stock for Q3 2018, up 6.4% quarter-over-quarter.
- 2 funds opened new NRX Pharmaceuticals positions in Q3 2018 and 1 closed out, a net change of +1 holder.
- The largest NRX Pharmaceuticals buyer in Q3 2018 was Longfellow Investment Management, an estimated $966K added.
- The largest NRX Pharmaceuticals seller in Q3 2018 was Glazer Capital LLC, an estimated $201K sold.
Based on aggregated 13F filings for Q3 2018.